Safety and Efficacy of IBI188 With Azacitidine in Newly Diagnosed Higher Risk MDS
Status:
Recruiting
Trial end date:
2022-02-20
Target enrollment:
Participant gender:
Summary
The study is to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA)
as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic
syndrome